UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000015288
Receipt No. R000017782
Scientific Title Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease
Date of disclosure of the study information 2014/09/30
Last modified on 2019/04/03 (Ver. 8)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease
Acronym Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease
Scientific Title Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease
Scientific Title:Acronym Before-after study of efficacy of morphine for dyspnea in patients with chronic obstructive pulmonary disease
Region
Japan

Condition
Condition COPD
Classification by specialty
Pneumology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The aim of this study is to investigate the efficacy of morphine for dyspnea in patients with COPD.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Dyspnea NRS change between before (Day 0 evening) and after morphine treatment (Day 2 evening)
Key secondary outcomes 1. Dyspnea NRS change between before (Day 0 morning) and after morphine treatment (Day 1 morning, Day 2 morning)
2. Dyspnea NRS change between before (Day 0 evening) and after morphine treatment (Day1 evening).
3. Respiratory rate, blood puressure, SpO2
4. Sleep disturbance
5. Nausea NRS, Somnolence NRS, Anorexia NRS,
6. Nausea and constipation grade in CTCAE v4.0
7. Sedation
8. Derilium
9. Other adverse effect
10. Spontaneous bowel movement

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Oral morphine 3mg or 2mg every 6 hours (total six times)
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Hospitalized patients with diagnosis of COPD based on the criteria of GOLD 2014 (FEV1/FVC<70%)
2. Patients with severe dyspnea at rest after standard treatment for dypnea
3. Patients aged 40 years-old or older at the time of obtaining informed consent
4. Patients with history of cigarette smoking of at least 10 pack-years
5. Patients who have the following data at baseline:
AST <= 100 IU/L
ALT <= 100 IU/L
T-BIL <= 2.0 mg/dL
eGFR >= 30 mL/min
SPO2 >= 90 % (Oxygen is allowed)
PaCO2 <= 60 Torr (Oxygen is allowed)
6. Patients who receive enough other treatment fo dyspnea of COPD
7. Patients with expected survival of 1 month or longer
8. Patients with lucidity and capability of communication and without cognitive inpairments
9. Patients who agree to participate the study with written informed consent
Key exclusion criteria 1. Patients with contraindication of morphine (ex. allergy for morphine and history of severe adverse effects of morphine)
2. Patients who use opioid. Patients who did not use codein within 3 days before study entry are eligble.
3. Patients with COPD acute exacerbation
4. Patients with active infection that causes dyspnea
5. Patients with lung cancer that causes dyspnea
6. Patients with pneumothorax
7. Patients who uses invasive positive airway pressure ventilation. Patients who uses nasal high flow were not excluded
8. Patients who changed the way of intaking of bronchodilators, corticosteroids, vasodilators and anxiolytics within two days before enrollment of the study
9. Patients who have or had drug abuse or drug dependence
10. Patients who are pregnant or possibly pregnant
11. Patients who are judged to be innapropriate for the study by the physician
Target sample size 35

Research contact person
Last name of lead principal investigator
1st name
Middle name
Last name Yoshinobu Matsuda
Organization National Hospital Organization Kinki-Chuo Chest Medical Center
Division name Department of Psychosomatic Internal Medicine
Zip code
Address 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
TEL 072-252-3021
Email ymatsuda@kch.hosp.go.jp

Public contact
1st name of contact person
1st name
Middle name
Last name Yoshinobu Matsuda
Organization National Hospital Organization Kinki-Chuo Chest Medical Center
Division name Department of Psychosomatic Internal Medicine
Zip code
Address 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, 591-8555, Japan
TEL 072-252-3021
Homepage URL
Email ymatsuda@kch.hosp.go.jp

Sponsor
Institute Non-Profit Organization JORTC
Institute
Department

Funding Source
Organization National Center for Geriatrics and Gerontology
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 09 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2014 Year 08 Month 26 Day
Date of IRB
2014 Year 09 Month 08 Day
Anticipated trial start date
2014 Year 10 Month 09 Day
Last follow-up date
2018 Year 02 Month 28 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2014 Year 09 Month 30 Day
Last modified on
2019 Year 04 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017782